

Supplemental Information

SUPPLEMENTAL TABLE 3 Schema Describing Classification of Childhood Cancer Cases Estimated to Be In Utero Before Versus Those Estimated to Be In Utero After Mandatory Fortification of Enriched Grain Products With Folic Acid in the United States in 1996–1998

Period	Year of Birth	Year of Diagnosis				
		Age 0 to <1 y	1 to <2 y	2 to <3 y	3 to <4 y	4 to <5 y
Prefortification	1986	1986	1987	1988	1989	1990
	1987	1987	1988	1989	1990	1991
	1988	1988	1989	1990	1991	1992
	1989	1989	1990	1991	1992	1993
	1990	1990	1991	1992	1993	1994
	1991	1991	1992	1993	1994	1995
	1992	1992	1993	1994	1995	1996
	1993	1993	1994	1995	1996	1997
	1994	1994	1995	1996	1997	1998
	1995	1995	1996	1997	1998	1999
	Excluded	1996	1996 ^a	1997 ^a	1998 ^a	1999 ^a
1997		1997 ^a	1998 ^a	1999 ^a	2000 ^a	2001 ^a
1998		1998 ^a	1999 ^a	2000 ^a	2001 ^a	2002 ^a
Postfortification	1999	1999	2000	2001	2002	2003
	2000	2000	2001	2002	2003	2004
	2001	2001	2002	2003	2004	2005
	2002	2002	2003	2004	2005	2006
	2003	2003	2004	2005	2006	2007
	2004	2004	2005	2006	2007	2008
	2005	2005	2006	2007	2008	2009 ^a
	2006	2006	2007	2008	2009 ^a	2010 ^a
	2007	2007	2008	2009 ^a	2010 ^a	2011 ^a
	2008	2008	2009 ^a	2010 ^a	2011 ^a	2012 ^a

^a Indicates years that were excluded from analysis (for cases estimated to be in utero during the years the fortification mandate was being implemented) or not yet published by SEER (2009 and beyond).

SUPPLEMENTAL TABLE 4 Pre- and Postfortification Frequencies and Incidence Rates, As Well As Incidence Rate Ratios Comparing the Periods, for Childhood Cancers Diagnosed in Infants Aged <1 Year in SEER 9 Catchment Areas

Cancer	Prefortification ^a			Postfortification ^b			Post-vs Prefortification	
	Count	IR ^c	95% CI	Count	IR ^c	95% CI	IRR	95% CI
All cancers	894	241.4	225.8–257.7	933	238.1	223.1–253.9	0.99	0.90–1.08
I Leukemias; myeloproliferative and myelodysplastic diseases	136	36.7	30.8–43.4	181	46.2	39.7–53.4	1.26 ^d	1.00–1.58 ^d
I(a) Lymphoid leukemias	70	18.9	14.7–23.9	82	20.9	16.6–26.0	1.11	0.80–1.55
I(b) Acute myeloid leukemias	45	12.1	8.9–16.3	72	18.4	14.4–23.1	1.51 ^d	1.03–2.25 ^d
III CNS and miscellaneous intracranial and intraspinal neoplasms	136	36.7	30.8–43.4	111	28.3	23.3–34.1	0.77 ^d	0.60–1.00 ^d
III(a.1) Ependymomas	18	4.9	2.9–7.7	14	3.6	2.0–6.0	0.74	0.34–1.56
III(b) Astrocytomas	52	14.0	10.5–18.4	45	11.5	8.4–15.4	0.82	0.54–1.24
III(c.1) Medulloblastomas	20	5.4	3.3–8.3	15	3.8	2.1–6.3	0.71	0.34–1.46
III(c.2) PNET	22	5.9	3.7–9.0	7	1.8	0.7–3.7	0.30 ^d	0.11–0.73 ^d
IV(a) Neuroblastoma and ganglioneuroblastoma	253	68.3	60.1–77.3	256	65.3	57.6–73.9	0.96	0.80–1.14
V Retinoblastoma	110	29.7	24.4–35.8	95	24.2	19.6–29.6	0.82	0.61–1.08
VI(a.1) Nephroblastoma (Wilms tumor)	67	18.1	14.0–23.0	43	11.0	7.9–14.8	0.61 ^d	0.40–0.90 ^d
VII(a) Hepatoblastoma	35	9.4	6.6–13.1	34	8.7	6.0–12.1	0.92	0.56–1.52
IX(a) Rhabdomyosarcomas	17	4.6	2.7–7.3	22	5.6	3.5–8.5	1.22	0.62–2.45
X Germ cell and trophoblastic tumors; neoplasms of gonads	62	16.7	12.8–21.5	85	21.7	17.3–26.8	1.30	0.92–1.83
Population	3 703 871			3 918 070				

^a Includes infants diagnosed at <1 year in 1986–1995.

^b Includes infants diagnosed at <1 year in 1999–2008.

^c IRs are calculated per 1,000,000 person-years.

^d Pre- and postfortification rates are statistically significantly different ($P < .05$).